Pneumonia News and Research

Latest Pneumonia News and Research

GAVI Alliance launches pneumonia vaccine project in Nicaragua

"A new vaccine against the most deadly forms of pneumonia, one of the world's biggest killers of children, [was] launched in Nicaragua [on Sunday] as part of an effort to prevent 700,000 deaths in poorer countries by 2015," Reuters reports (Kelland, 12/10).

14 Dec 2010

Prevenar 13 launched in first childhood immunization program for PD in Nicaragua

Pfizer Inc. announced that Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today. The AMC is an innovative program which involves private-public partnerships to help make newer vaccines available on a sustainable, affordable and accelerated basis to the least developed countries.

13 Dec 2010

Rate of health care-associated infections in developing countries more than double U.S., European rates, study finds

The rate of health care-associated infections in developing countries is more than three times the rate of cases in the U.S. and more than double the rate in Europe, according to a study published Friday in the Lancet, BBC reports (12/9).

13 Dec 2010

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

COPD becomes third leading cause of death in the U.S.

The Centers for Disease Control (CDC) and Prevention's National Center for Health Statistics (NCHS) released a report today, "Deaths: Preliminary Data for 2008," confirming that Chronic Obstructive Pulmonary Disease (COPD) became the third leading cause of death in the U.S. for 2008.

10 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Downstream cancer care linked to complications during surgery

Patients who have complications after colorectal cancer surgery are less likely to get chemotherapy, even when it is clearly recommended for their diagnosis, a new study from the University of Michigan Comprehensive Cancer Center finds.

9 Dec 2010

First Edition: December 7, 2010

In today's headlines, Senate leaders appear to be nearing a one-year deal on Medicare's physician pay problem.

7 Dec 2010

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.

7 Dec 2010

Campaign to inoculate millions across Africa against meningitis kicks off in Burkina Faso

On Monday, a campaign started in Burkina Faso to "inoculate tens of millions of West Africans with a new vaccine in what scientists hope will be the beginning of the end of ravaging meningitis epidemics" across the continent, the New York Times reports.

7 Dec 2010

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.

7 Dec 2010

Screening for CCDC40 gene mutations may help determine risk for congenital heart defects

A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.

7 Dec 2010

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

Today, Lundbeck Inc. presented positive data from its pivotal phase III study to determine the efficacy and safety profiles of the investigational compound clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.

6 Dec 2010

HHS, CCSC establish new national awards program

The US Department of Health and Human Services and the Critical Care Societies Collaborative have established a new national awards program. The National Awards Program to Recognize Achievements in Eliminating Healthcare-Associated Infections will annually recognize teams of critical care professionals and healthcare institutions that achieve excellence and notable, sustained improvements in preventing healthcare-associated infections, specifically infections in critical care.

4 Dec 2010

New national awards program to recognize healthcare institutions to eliminate HAI infection

A new national awards program will recognize teams of critical care professionals and healthcare institutions able to successfully reduce or eliminate healthcare-associated infections (HAI), a leading cause of death in the United States.

3 Dec 2010

OHA launches 2010 guidebook on leading practices in patient safety

The Ontario Hospital Association (OHA) launched the 2010 Guidebook on Leading Practices in Patient Safety entitled "Advancing Patient Safety through Ideas and Innovations", during this year's HealthAchieve.

2 Dec 2010

FDA grants 510(k) clearance to Focus Diagnostics Simplexa Flu A/B & RSV test on 3M Integrated Cycler

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance to the Focus Diagnostics Simplexa Flu A/B & RSV test on the 3M™ Integrated Cycler. The Simplexa test, developed and manufactured by Quest Diagnostics' Focus Diagnostics business, is intended as an aid in the detection and discrimination of influenza A, influenza B and RSV virus infections.

From Quest Diagnostics 2 Dec 2010

More effective treatment for severe form of influenza

Flu season is upon us and while getting the nasty bug is bad news, the good news is it's now possible to treat the severe form of the virus more effectively, according to a Ryerson University researcher. Though Canada is not expecting a pandemic flu season this winter Health Canada reports that about 4,000 to 8,000 Canadians die each year from flu-related pneumonia.

2 Dec 2010

FDA approves CUBICIN 2-minute IV injection for MRSA skin infections, bacteremia

Cubist Pharmaceuticals, Inc. today announced that its currently-marketed antibiotic, CUBICIN (daptomycin for injection), has been approved by the U.S. Food & Drug Administration (FDA) for once-a-day dosing as a 2-minute intravenous (IV) injection.

2 Dec 2010

New experimental device could offer effective treatment option for people with swallowing disorders

In what might be one of the world's first medicinal body piercings, UC Davis Health System surgeons announced today that they have successfully implanted an experimental device in the throat of a man that will enable him to manually control his ability to swallow.

1 Dec 2010

Pneumonia News and Research

Latest Pneumonia News and Research

GAVI Alliance launches pneumonia vaccine project in Nicaragua

Prevenar 13 launched in first childhood immunization program for PD in Nicaragua

Rate of health care-associated infections in developing countries more than double U.S., European rates, study finds

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

COPD becomes third leading cause of death in the U.S.

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Downstream cancer care linked to complications during surgery

First Edition: December 7, 2010

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Campaign to inoculate millions across Africa against meningitis kicks off in Burkina Faso

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

Screening for CCDC40 gene mutations may help determine risk for congenital heart defects

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

HHS, CCSC establish new national awards program

New national awards program to recognize healthcare institutions to eliminate HAI infection

OHA launches 2010 guidebook on leading practices in patient safety

FDA grants 510(k) clearance to Focus Diagnostics Simplexa Flu A/B & RSV test on 3M Integrated Cycler

More effective treatment for severe form of influenza

FDA approves CUBICIN 2-minute IV injection for MRSA skin infections, bacteremia

New experimental device could offer effective treatment option for people with swallowing disorders

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Pneumonia News and Research

Latest Pneumonia News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in